Balance Sheet (Annual)

CBOE / CBOE Holdings, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 134,936 135,597 221,341 147,927 102,253 97,298 143,500
    Marketable Securities Current - - - - - - 47,300
    Accounts Receivable Net Current 37,578 45,666 49,888 58,386 62,535 69,902 217,300
    Income Taxes Receivable - - 22,039 21,503 27,901 53,708 17,200
    Other Assets Current 1,065 567 2,717 972 625 134 9,400
    Assets Current 189,682 202,909 308,861 244,107 204,118 235,045 434,700
  Investments In Affiliates Subsidiaries Associates And Joint Ventures - - - - - - 82,700
  Land 4,914 4,914 4,914 4,914 4,914 4,914 4,900
  Property Plant And Equipment Excluding Land Net - - - - - - 73,900
  Goodwill - - - - 7,655 26,468 2,707,400
  Intangible Assets Net Excluding Goodwill - - - - 2,378 8,666 1,902,600
  Other Assets Noncurrent - - - - - - 59,500
  Assets 327,868 338,858 441,589 383,901 384,788 476,615 5,265,700
Liabilities And Stockholders Equity
  Liabilities Current
    Accounts Payable And Accrued Liabilities Current 46,071 45,148 52,958 58,566 60,104 79,400 153,800
    Regulatory Fees Payable Current - - - - - - 105,600
    Contract With Customer Liability Current - - - - - - -
    Accrued Income Taxes Current - - - 1,774 1,633 18 2,600
    Business Combination Contingent Consideration Liability Current - - - - 2,000 0 56,600
    Liabilities Current 52,287 52,150 107,458 73,665 73,997 89,843 334,000
  Long Term Debt Noncurrent - - - - - - 1,237,900
  Accrued Income Taxes Noncurrent 12,185 20,857 29,903 40,683 39,679 52,100 78,800
  Deferred Income Tax Liabilities Net - - - - - 0 488,200
  Other Liabilities Noncurrent 3,906 3,946 3,856 4,197 2,883 2,283 6,800
  Commitments And Contingencies - - - - - - -
  Redeemable Noncontrolling Interest Equity Carrying Amount - - - - - 12,600 9,400
  Stockholders Equity Including Portion Attributable To Noncontrolling Interest
    Preferred Stock Value 0 0 0 0 0 0 -
    Common Stock Value - - - - - 929 1,200
    Treasury Stock Common Value - - - - - - 558,300
    Additional Paid In Capital - - - - - - 2,623,700
    Retained Earnings Accumulated Deficit 232,121 275,491 349,290 472,005 603,597 710,779 993,300
    Accumulated Other Comprehensive Income Loss Net Of Tax -899 -893 -1,050 -689 -824 -762 50,700
    Stockholders Equity - - 284,517 250,067 259,645 317,946 3,110,600
  Liabilities And Stockholders Equity 327,868 338,858 441,589 383,901 384,788 476,615 5,265,700

Peers - Security And Commodity Brokers, Dealers, Exchanges, And Services (62)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 12503M108